What is the Apellis Pharmaceuticals Inc. stock price forecast?

Apellis Pharmaceuticals Inc. is currently trading at $41.03. View real-time AI analysis on Alpha Lenz.

What is Apellis Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Apellis Pharmaceuticals Inc. on Alpha Lenz.

What is Apellis Pharmaceuticals Inc.'s P/E ratio?

Apellis Pharmaceuticals Inc.'s P/E ratio is 231.2.

Apellis Pharmaceuticals Inc.

NASDAQ · APLS

$41.03+0.00(+0.00%)Pre-market

Ask about Apellis Pharmaceuticals Inc.'s future dividend policy...

Alpha Chat Insight

“Apellis Pharmaceuticals Inc. trades at a P/E of 231.2 (premium valuation) with modest ROE of 7.5%. 3Y revenue CAGR of 137.0% highlights clear growth momentum.”

Ask for details →

Company Overview

Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.

CEODr. Cedric Francois M.D., Ph.D.

Websitehttps://apellis.com

SectorHealthcare

IndustryBiotechnology

Employees705

Company Statistics

FY 2025

Profile

$5.18BMarket Cap

$1.00BRevenue

0.00Shares Out

705Employees

Margins

89.81%Gross

6.97%EBITDA

5.52%Operating

2.40%Pre-Tax

2.23%Net

Valuation

231.18P/E

13.98P/B

5.16EV/Sales

74.06EV/EBITDA

114.98P/FCF

Growth (CAGR)

136.98%Rev 3Yr

31.98%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

2.28%ROA

7.48%ROE

6.98%ROIC

Financial Health

$466.23MCash & Cash Equivalents

$238.88MNet Debt

190.49%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Apellis Pharmaceuticals Inc. trades at a P/E of 231.2 (premium valuation) with modest ROE of 7.5%. 3Y revenue CAGR of 137.0% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Apellis Pharmaceuticals Inc. (ticker: APLS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 705 employees. Market cap is $5.2B.

The current price is $41.03 with a P/E ratio of 231.18x and P/B of 13.98x.

ROE is 7.48% and operating margin is 5.52%. Annual revenue is $1.0B.